Clinical

Articles

The addition of lenalidomide to rituximab continued to improve survival outcomes with durable responses among patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.

Lenalidomide Plus Rituximab Continues to Improve PFS With Manageable Safety in Lymphoma Subtypes

Phase 1 data presented at 2021 EHA indicate that a high rate of response was associated with zandelisib plus zanubrutinib therapy in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia. 

Zandelisib/Zanubrutinib Combination in R/R CLL and B-Cell Malignancies Shows Clinical Benefit

The CAR T-cell therapy lisocabtagene maraleucel resulted in better efficacy versus standard of care with no new safety signals.

Liso-Cel Meets Primary End Point of Event-Free Survival Improvement in Phase 3 Trial

The combination of mosunetuzumab plus polatuzumab vedotin showed positive efficacy and safety data in a phase 1b study of patients with B-cell non-Hodgkin lymphoma.

Mosunetuzumab Plus Polatuzumab Vedotin to Treat R/R B-NHL Effective and Well Tolerated

An observational cohort study revealed that BEAM therapy led to subpar outcomes compared with thiotepa-based treatment for patients requiring conditioning regimens for primary central nervous system lymphoma. 

Thiotepa Conditioning Regimens Improve Survival in Primary Central Nervous System Lymphoma

An off-the-shelf cellular therapy that combines Epstein Barr Virus–Specific T cells and a CD30-targeting chimeric antigen receptor product demonstrated safety and early efficacy in a group of patients with CD30-positive lymphomas. 

Allogeneic CAR T-Cell Product Shows Early Promise for Patients With CD30+ Lymphomas

The 3-year follow-up analysis of 4 treatment groups who received CNS prophylaxis found a decreased incidence of CNS relapse for patients with high-risk diffuse large B-cell lymphoma, although the data were not statistically significant.

Real-World Data Suggest Systemic High-Dose and Intrathecal MTX Lower CNS Relapse Incidence for DLBCL

Videos

The lymphoma expert discussed how adding copanlisib to rituximab improved progression-free survival, while demonstrating a manageable safety profile in patients with relapsed indolent non-Hodgkin lymphoma.

Matthew J. Matasar, MD, on the Clinical Implications of the Phase 3 CHRONOS-3 Study

The lymphoma expert offered highlights from the meeting, with hopes that more treatment options will be available for patients with lymphoma.

Matthew J. Matasar, MD, Discusses ‘Breadth of Scientific Investigation’ at AACR Annual Meeting

Patients treated in a multicenter trial experienced a median progression-free survival of 13.2 months with pembrolizumab versus 8.3 months in those receiving brentuximab vedotin.

Lymphoma | Topics